On September 14th, RudaCure held a briefing session for shareholders to provide an update on recent achievements and current business activities, and to foster mutual understanding and continued cooperation.
We thank the shareholders who attended, and we will maintain our shareholder-first management approach based on the information discussed and shared on the day, while doing our utmost to achieve our drug development goals.
We hope you will continue to watch RudaCure grow and cheer us on.
Thank you.